Additional baricitinib loading dose improves clinical outcome in COVID-19

Pneumonia associated with coronavirus disease 2019 (COVID-19) has been accounted for high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of standard and effective anti-inflammatory drug in COVID-19 pneumonia management is a big challenge. Baricitinib, a Janus kinase (JA...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, Md Jahidul, Rabbani, Raihan, Anam, Ahmad Mursel, Huq, Shihan Mahmud Redwanul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729634/
https://www.ncbi.nlm.nih.gov/pubmed/33364433
http://dx.doi.org/10.1515/med-2021-0010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729634/
https://www.ncbi.nlm.nih.gov/pubmed/33364433
http://dx.doi.org/10.1515/med-2021-0010

Ejemplares similares